Nextcure Transforms Into Avere as Investors Back Oral Psoriasis Therapy

The Avere-NextCure merger creates AVRX, a Nasdaq-listed vehicle to advance AVR-001, an oral IL-23 inhibitor. A $320M financing and Hansoh licensing support psoriasis and UC programs; NXTC gets 90% CVR and ~1.21% stake. The closing is targeted for 2H 2026, with Phase 2b results anticipated in 2027–28.

Avere–NextCure merger forms AVRX; NXTC gains minority stake and CVR

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

NextCure partnered with Simcere Zaiming for a $745 million cancer therapy deal. This collaboration aims to develop treatments for solid tumors.

NXTC

NXTC price chart

Avere–NextCure merger forms AVRX; NXTC gains minority stake and CVR

NextCure signs up to $745 million deal with China's Simcere to develop cancer drug

Company intelligence